Hypertension in the elderly and the very old

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 6, 2009, Pages 659-665

  Casiglia, Edoardo ^a   Tikhonoff, Valérie ^a   Pessina, Achille C ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Epidemiology; Population; Pulse hypertension; Pulse pressure; Systolic blood pressure; Very old

Indexed keywords

DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ANTIHYPERTENSIVE AGENT;

BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; ELDERLY CARE; GENETIC RISK; GENOTYPE; HUMAN; HYPERTENSION; LIFESTYLE; MORTALITY; PREVALENCE; PROGNOSIS; PULSE PRESSURE; REVIEW; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; VERY ELDERLY; AGE; AGED; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; DRUG EFFECT; PATHOPHYSIOLOGY; RISK FACTOR;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; RISK FACTORS;

EID: 68849131035     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.17     Document Type: Review

References (82)

1. Casiglia E, Spolaore P, Mormino P et al. The CASTEL project (Cardiovascular Study in the Elderly): protocol, study design, and preliminary results of the initial survey. Cardiologia 36, 569-576 (1991).
2. Casiglia E, Palatini P. Cardiovascular risk factors in the elderly. J. Hum. Hypertens. 12, 575-581 (1998).
3. Casiglia E, Mazza A, TikhonoffV et al. Protocol and experimental design of the LEOGRA (Last Evidences Of Genetic Risk factors in the Aged) study, a population-based genetic approach to cardiovasclar risk. J. Hypertens. 18 (Suppl. 2), 174 (2000).
4. Casiglia E, Basso G, Guglielmi F et al. German origin clusters for high cardiovascular risk in an italian enclave. Int. Heart. J. 46, 489-500 (2005).
5. Ambrosio GB, Zamboni S, Gabaldo S et al. Screening of hypertension in a community. Data from the Camposampiero Project. G. Ital. Cardiol. 8, 1161-1167 (1978).
6. Ambrosio GB, Zamboni S, Vanuzzo D et al. Prevalene of arterial hypertension in the community. Experience of the province of Veneto. G. Ital. Cardiol. 10, 1280-1287 (1980).
7. Ginocchio G, Staessen JA, Casiglia E, D'Este D, Fagard R, Pessina AC. Life-style and blood pressure. The Mirano study. J. Hypertens. 15 (Suppl. 4), 106 (1997).
8. Casiglia E, D'Este D, Ginocchio G et al. Lack of influence of menopause on blood pressure and cardiovascular risk profile. J. Hypertens. 14, 729-736 (1996).
9. Casiglia E, Ginocchio G, Tikhonoff V et al. Blood pressure and metabolic profile after surgical menopause. Comparison with fertile and naturally-menopausal women. J. Hum. Hypertens. 14, 799-806 (2000).
10. Kuznetsova T, Staessen JA, Kawecka-Jaszcs K et al. Quality control of the blood pressure phenotype in the European Project on Genes in Hypertension. Blood Press. Monit. 7, 251-224 (2002).
11. Casiglia E, TikhonoffV, Mazza A, Pessina AC. Systolic and pulse hypertension. Aging Health 1, 85-94 (2005).
12. Williams B, Lindholm LH, Sever P. Systolic pressure is all that matters. Lancet 371, 2219-2220 (2008).
13. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289, 2560-2572 (2003).
14. Casiglia E, Mazza A, Tikhonoff V et al. Arterial hypertension and mortality in the elderly. Am. J. Hypertens. 15, 958-966 (2002).
15. Casiglia E, Spolaore P, Ginocchio G et al. Mortality in very old subjects aged 80 years or over. The CASTEL (Cardiovascular Study in the Elderly). Eur. J. Epidemiol. 9, 577-586 (1993).
16. Meeks WM. Pathophysiology of hypertension in the elderly. Sem. Nephrol. 22, 65-70, (2002).
17. Elliott RJ, McGrath LT. Calcification of the human thoracic aorta during age. Calcif. Tissue. Int. 54, 268-273 (1994).
18. Dart AM, Kingwell BA. Pulse pressure - a review of mechanisms and clinical relevance. JACC 37, 975-984 (2001).
19. Nichols WW, O'Rouke MF, Avolio AP et al. Effects of age on ventricular-vascular coupling. Am. J. Cardiol. 15, 1179-1184 (1985).
20. Smulyan H, Safar M. Systolic blood pressure revisited. JACC 29, 1047-1113 (1997).
21. Safer ME, Laurent P. Pulse pressure and arterial stiffness in rats. Comparison with humans. Am. J. Physiol. Heart Circ. Physiol. 285, 1363H-1369H (2003).
22. Casiglia E, Mazza A, Tikhonoff V et al. Weak effect of hypertension and other classic risk factors in the elderly who have already paid their toll. J. Human. Hypert. 16, 21-31 (2002).
23. Pavan L, Casiglia E, Pauletto P et al. Blood pressure, serum cholesterol and nutritional state in Tanzania and in Amazons. Comparison with an Italian population. J. Hypertens. 15, 1083-1090 (1997).
24. Pavan L, Casiglia E, Carvalho Braga LM et al. Effects of a traditional lifestyle on the cardiovascular risk profile. The Amondava population of the Brazilian Amazon. Comparison with matched African, Italian and-Polish populations. J. Hypertens. 17, 749-756 (1999).
25. Pauletto P, Puato M, Caroli MG et al. Blood pressure and atherogenic lipoprotein profiles of fish-diet and vegetarian villagers in Tanzania. The Lugalawa study. Lancet 348, 784-788 (1996).
26. Palatini P, Palomba D, Bertolo O et al. The white-coat effect is unrelated to the difference between clinic and daytime blood pressure and is associated with greater reactivity to public speaking. J. Hypertens. 21, 545-553 (2003).
27. Timio M, Lippi G, Venanzi S et al. Blood pressure trend and cardiovascular events in nuns in a secluded order. A 30-year follow-up study. Blood Press. 6, 81-87 (1997).
28. Davies E, Holloway CD, Ingram MC et al. Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2. Hypertension 33, 703-707 (1999).
29. Barbato A, Russo P, Siani A et al. Aldosterone synthase gene (CYP11B2) C-344T polymorphism, plasma aldosterone, renin activity and blood pressure in a multi-ethnic population. J. Hypertens. 22, 1895-1901 (2004).
30. Matsubara M, Sato T, Nishimura T et al. CYP11B2 polymorphisms and home blood pressure in a population-based cohort in Japanese. The Ohasama study. Hypertens. Res. 27, 1-6 (2004).
31. Zhu H, Sagnella GA, Dong Y et al. Contrasting associations between aldosterone synthase gene polymorphisms and essential hypertension in blacks and in whites. J. Hypertens. 21, 87-95 (2003).
32. Staessen J, Wang JG, Brand E et al. Effects of three candidate genes on prevalence and incidence of hypertension in a Caucasian population. J. Hypertens. 19, 1349-1358 (2001).
33. Tikhonoff V, Kuznetsova T, Stolarz K et al. Modulation of genetic cardiovascular risk by age and lifestyle. Curr. Cardiovasc. Risk Rep. 2(5), 398-404 (2008).
34. Casiglia E, Tikhonoff V, Mazza A et al. C-344T polymorphis of the aldosterone synthase gene and blood pressure in the elderly: a population-based study. J. Hypertens. 23, 1991-1996 (2005).
35. Casiglia E, Tikhonoff V, Schiavon L. et al. Skinfold thickness and blood pressure across C-344T polymorphism of CYP11B2 gene. J. Hypertens. 25, 1828-1833 (2007).
36. Kuznetsova T, Staessen JA, Brand E et al. Sodium excretion as a modulator of genetic associations with cardiovascular phenotypes in the european project on genes in hypertension. J. Hypertens. 24, 235-242 (2006).
37. Tikhonoff V, Kuznetsova T, Stolarz K et al. B-adducin polymorphism, blood pressure, and sodium excretion in three European populations. Am. J. Hypertens. 16, 840-846 (2003).
38. Stolarz K, Staessen JA, Kawecka-Jaszcz K et al. Genetic variation in CYP11B2 and AT1R influences heart rate variability conditional on sodium excretion. Hypertension 44, 156-162 (2004).
39. Kuznetsova T, Staessen JA, Thjis L et al. Left ventricular mass in relation to genetic variation in angiotensin ii receptors, renin system genes, and sodium excretion. Circulation 110, 2644-2650 (2004).
40. Kuznetsova T, Staessen JA, Reineke T et al. Context-dependency of the relation between left ventricular mass and AGT gene variants. J. Hum. Hypertens. 19, 155-163 (2005).
41. Kuznetsova T, Staessen JA, Stolarz K et al. Relationship between left ventricular mass and the ace d/i polymorphism varies according to sodium intake. J. Hypertens. 22, 287-295 (2004).
42. Casiglia E, Tikhonoff V, Mazza A et al. Pulse pressure and coronary mortality in elderly men and women from general population. J. Hum. Hypertens. 16, 611-620 (2002).
43. Mazza A, Pessina AC, Privato G, Tikhonoff V, Pavei A, Casiglia E. Pulse pressure: an independent predictor of coronary and stroke mortality in elderly females from the general population. Blood Press. 10, 205-211 (2001).
44. Stokes GS. Systolic hypertension in the elderly. Pushing the frontiers of therapy - a suggested new approach. J. Clin. Hypertens. 6, 192-197 (2004).
45. Staessen JA, Gasowski J, Wang JG et al. Risks of untreated and treated isolated systolic hypertension in the elderly. Meta-analysis of outcome trials. Lancet 11, 355, 865-872 (2000).
46. Aviv A. Pulse pressure and human longevity. Hypertension 37, 1060-1066 (2001).
47. Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham heart study. Circulation 100,354-360 (1999).
48. Franklin SS. Arterial stiffness and hypertension. A two-way street? Hypertension 45, 349-351 (2005).
49. Casiglia E, Tikhonoff V, Mazza A, Pessina AC. Systolic and pulse hypertension. Aging Health 1, 85-94 (2005).
50. Casiglia E, Maniati G, Daskalakis C et al. Left ventricular hypertrophy in the elderly. Unreliability of electrocardiographic criteria in 477 subjects ages 65 years or more. The Cardiovascular Study in the Elderly (CASTEL). Cardiology 87, 429-435 (1996).
51. Casiglia E, Daskalakis C, Maniati G et al. Left ventricular hypertrophy is not a predictor of mortality in the elderly. High BP 6, 12-21 (1997).
52. Casiglia E, Spolaore P, Ginocchio G et al. Predictors of mortality in very old subjects aged 80 years or over. Eur. J. Epidemiol. 9, 577-586 (1993).
53. Dal Palù C, Casiglia E, Pessina AC. The CASTEL (Cardiovascular Study in the Elderly). Prediction of cariovascular mortality in a general population aged 65 years or over. In: World Hypertension League Yearbook 2000-2001. World Hypertension League, Burnaby, Canada (2001).
54. Casiglia E, Spolaore P, Ginocchio G et al. Proteinuria predicts mortality among elderly but not among very old subjects. J. Nephrol. 5, 89-93 (1993).
55. Casiglia E, Ginocchio G, Spolaore P et al. Only uric acid and FEV1 are predictors of mortality in very old subjects. Acta Cardiol. 48, 290-292 (1993).
56. Mazza A, Tikhonoff V, Casiglia E, Pessina AC. Body mass index and mortality in the elderly from general population. Gerontology 53, 36-45 (2007).
57. Casiglia E, Tikhonoff V. Inflammatory and coagulative markers of atherosclerosis. Eur. Heart J. 28, 271-273 (2007).
58. Gueyffier F, Bulpitt C, Boissel JP et al. Antihypertensive drugs and very old people: a subgroup meta-analysis of randomised controlled trials. Lancet 353, 793-796 (1999).
59. Pessina AC, Casiglia E. Are hypertensive patients undentreated? Aging Health 1, 355-357 (2006).
60. Casiglia E, Mazza A, Tikhonoff V, Pessina AC. Population-based studies improve outcome in hypertensive patients. Am. J. Hypertens. 15, 605-608 (2002).
61. Casiglia E, Saugo M, Schiavon L et al. Reduction of cardiovascular risk and mortality. A population-based study. Adv. Ther. 23, 905-920 (2006).
62. Tikhonoff V, Casiglia E, Nawrot T, Staessen JA. Should high-normal blood pressure be treated? J. Hypertens. 20, 1-2 (2002).
63. Casiglia E, Spolaore P, Mazza A et al. Effects of two different therapeutic approaches on total and cardiovascular mortality in the CArdiovascular STudy in the ELderly (CASTEL). Jap. Heart J. 35, 589-600 (1994).
64. Firdaus M, Sivaram CA, Reynolds DW. Prevention of cardiovascular events by treating hypertension in older adults. An evidence-based approach. J. Clin. Hypertens. (Greenwich) 10, 219-225 (2008).
65. Blacher J, Staessen JA, Girend X et al. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch. Inter. Med. 160, 1085-1089, 2000.
66. Smulyan H, Safar ME. The diastolic blood pressure in systolic hypertension. Ann. Intern. Med. 132, 233-237 (2000).
67. Benetos A, Thomas F, Safar ME, Bean KE, Guize L. Should diastiolic and systolic blood pressure be considered for cardiovascular risk evaluation: a study in middle-aged men and women. J. Am. Coll. Cardiol. 37, 163-168 (2001).
68. Aronow WS. Treatment of hypertension in the elderly. Geriatrics 63, 21-25 (2008).
69. Berlowitz DR, Ash AS, Hockey EC et al. Inadeguate management of high blood pressure in a hypertensive population. N. Engl. J. Med. 339, 1957-1963 (1998).
70. Banegas J, Rodrigues-Artalejo F, Ruilope M et al. Hypertension magnitude and management in the elderly population of Spain. J. Hypertens. 20, 2157-2164 (2002).
71. Staessen JA, Thjis L, Fagard R et al. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J. Hypertens. 22, 847-857 (2004).
72. Michak JL, Carter BL, Ardery G, Dawson JD, Harmston M, Franciscus CL. Physician adherence to blood pressure guidelines and its effect on seniors. Pharmacotherapy 28, 843-851 (2008).
73. Lloyd-Jones DM, Evans JC, Larson MG, Levy D. Treatment and control of hypertension in the community. A prospective analysis. Hypertension 40, 640-646 (2002).
74. Psati BM, Manolio TA, Smith NL et al. Time trends in high blood pressure control and the use of antihypertensive medications in older adults. Arch. Intern. Med. 162, 2325-2332 (2002).
75. Alam M, Barri YM. Systolic blood pressure is the main aetiology of poorly controlled hypertension. Am. J. Hypertens. 16, 140-143 (2003).
76. Kannel WB. Prevalence and implications of uncontrolled systolic hypertesion. Drugs Aging 20, 277-286 (2003).
77. Waeber B, Mourad JJ. Targeting systolic blood pressure: the key to control combined systolic/diastolic hypertension. Am. J. Hypertens. 19, 985-986 (2006).
78. Oliveira SA, Lapuerta P, McCarthy BD et al. Physician-retated barriers to the effective management of uncontrolled hypertension. Arch. Intern. Med. 162, 413-420 (2002).
79. Zanchetti A. Target blood pressure in elderly hypertensive patients: how low should you go? Blood Press. 2(Suppl.), 7-11 (2000).
80. Forette F, Seux MI, Staessen JA et al. Prevention of dementia in randomized double-blind placebo-controlled Systolic Hypertension in Europe Trial. Lancet 352, 1347-1351 (1998).
81. Martin-Schild S, Hallevi H, Albright KC et al. Aggressive blood pressure-lowering treatment before intravenous plasminogen activator therapy in acute ischemic stroke. Arch. Neurol. 65, 1174-1178 (2008).
82. Thjis L, Staessen JA, Beleva S et al. How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe follow-up study. Curr. Control Trials Cardiovasc. Med. 2, 298-306 (2001).